Aggressive prolactinoma (Review)
- 24 November 2021
- journal article
- review article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 23 (1) , 1-6
Abstract
Aggressive prolactinoma (APRL) is a subgroup of aggressive pituitary tumors (accounting for 10% of all hypophyseal neoplasia) which are defined by: invasion based on radiological and/or histological features, a higher proliferation profile when compared to typical adenomas and rapidly developing resistance to standard medication/protocols in addition to an increased risk of early recurrence. This is a narrative review focusing on APRL in terms of both presentation and management. Upon admission, the suggestive features may include increased serum prolactin with a large tumor diameter (mainly >4 cm), male sex, early age at diagnosis (2, Ki-67 proliferation index ≥3%, the need for radiotherapy, lack of response in terms of controlling prolactin levels and tumor growth despite multimodal therapy. However, none of these as an isolated element serves as a surrogate of APRL diagnosis. A fourth-line therapy is necessary with temozolomide, an oral alkylating chemotherapeutic agent, that may induce tumor reduction and serum prolactin reduction in 75% of cases but only 8% have a normalization of prolactin levels. Controversies surrounding the duration of therapy still exist; also regarding the fifth-line therapy, post-temozolomide intervention. Recent data suggest alternatives such as somatostatin analogues (pasireotide), checkpoint inhibitors (ipilimumab, nivolumab), tyrosine kinase inhibitors (TKIs) (lapatinib), and mTOR inhibitors (everolimus). APRL represents a complex condition that is still challenging, and multimodal therapy is essential.Keywords
This publication has 78 references indexed in Scilit:
- Macroprolactinomas in Children and Adolescents: Factors Associated With the Response to Treatment in 77 PatientsThe Journal of Clinical Endocrinology & Metabolism, 2015
- ProlactinomasEndocrinology and Metabolism Clinics of North America, 2015
- Aggressive Pituitary TumorsNeuroendocrinology, 2015
- Challenges and controversies in the treatment of prolactinomasExpert Review of Endocrinology & Metabolism, 2014
- Current Understanding of the Molecular Biology of Pancreatic Neuroendocrine TumorsJNCI: Journal of the National Cancer Institute, 2013
- Inhibition of PI3K/AKT/mTOR Pathway Enhances Temozolomide-Induced Cytotoxicity in Pituitary Adenoma Cell Lines in Vitro and Xenografted Pituitary Adenoma in Female Nude MiceEndocrinology, 2013
- Temozolomide in aggressive pituitary adenomas and carcinomasClinics, 2012
- Prolactinomas: diagnosis and treatmentExpert Review of Endocrinology & Metabolism, 2012
- Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitroEndocrine-Related Cancer, 2009
- Galactocele and prolactinoma—A pathogenic association?Maturitas, 2009